Navigation Links
PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
Date:10/23/2007

Expands global footprint for drug development services

WILMINGTON, N.C., Oct. 23 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the opening of offices in Sydney, Australia; Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru; reflecting continued expansion of its Phase II-IV services in key therapeutic areas.

The four new offices broaden the company's global footprint for delivering clinical services in response to increasing client demand. With an office in Melbourne, Sydney is PPD's second location in Australia. Offices in Copenhagen, Lisbon and Lima establish PPD's physical presence in those countries.

"With the biopharmaceutical industry increasingly relying on outsourcing, these new offices are important to our strategic growth in areas where there is high demand for our global experience and therapeutic expertise," said Fred Eshelman, chief executive officer of PPD. "We will continue to execute our globalization strategy by positioning our people, systems and infrastructure in locations that meet the needs of our clients."

PPD's Sydney office is based at 1 Pacific Highway, North Sydney, and the Copenhagen office is at Regus South Harbour at Sluseholmen 2-4. The Lisbon office is at Avenida da Liberdade, 110-1, and the Lima office is located at the Centro Empresarial Real -- San Isidro Edificio Real Seis, Piso 7. For more information about PPD services provided at Sydney, Copenhagen and Lisbon, call +1 919 456 4402, and for Lima, call +1 910 558 6789.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the opening of new offices and our globalization strategy, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5890

sueann.pentecost@rtp.ppdi.com

Analysts/Investors:

Steve Smith

+910 558 7585

stephen.smith@wilm.ppdi.com


'/>"/>
SOURCE PPD, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), is pleased to provide an update ... (now owned by Spectranetics Corporation (NASDAQ: SPNC ... Court of Appeals for the Federal ... court order (the "DCO").   The DCO had dismissed ...
(Date:2/10/2016)... och PITTSBURGH , 10 ... inte, och detta pressmeddelande får inte distribueras, ... till, och inga anmälningssedlar kommer att accepteras ... något land där Erbjudandet, distribution av detta ... skulle strida mot tillämpliga lagar eller regler ...
(Date:2/10/2016)... -- --> --> ... Spectroscopy Market by Industry (Oil & Gas, Petrochemical, Pharmaceutical, Water ... & Mining, and Others), And Geography - Global Forecast ... expected to grow to USD 3.9 Billion by 2020, ... 2020. Browse 82 market data Tables and ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... The annual list ... on evaluation of DataPoint’s team dedication and commitment to the SharePoint ecosystem. ... the annual list. The panel’s goal is to recognize and promote technology entrepreneurship. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical Group ... the heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, VA. ... level of medical care in the convenience of their homes, offices or at the ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... have become more actively engaged in health and wellness best practices in the ... of riding this trend. February is American Heart Month, which acts as an ...
(Date:2/11/2016)... PORTLAND, Ore. (PRWEB) , ... February 11, 2016 ... ... found Medicaid coverage results in significantly higher rates of several common cancer screenings, ... early, resulting in better outcomes and survival rates. , The study,“What Does ...
Breaking Medicine News(10 mins):